AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2281066 — intervention group
Group type: EXPERIMENTAL
Intervention: adrenaline
Number of subjects: 120
Study 2281066 — intervention group
Group type: EXPERIMENTAL
Intervention: theophylline administered via a gastric tube
Number of subjects: 120
Study 2281066 — intervention group
Group type: COMPARATOR
Intervention: isotonic saline solution
Number of subjects: 120
Study 28936 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (0.5 mg intravenously)
Number of subjects: 22
Study 28936 — intervention group
Group type: EXPERIMENTAL
Intervention: Etilefrine (0.25 mg/min)
Number of subjects: 22
Study 28936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30177302 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 12 months
Number of subjects: 100
Study 30177302 — intervention group
Group type: COMPARATOR
Intervention: No CPAP treatment
Number of subjects: 100
Study 29369301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1000 mg)
Number of subjects: 142
Study 29369301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 25631258 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% PQ10 gel
Number of subjects: 0
Study 25631258 — intervention group
Group type: COMPARATOR
Intervention: 0.3% HPMC (control group)
Number of subjects: 0
Study 25764779 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cryotherapy combined with kinesitherapy
Number of subjects: 56
Study 25764779 — intervention group
Group type: COMPARATOR
Intervention: Kinesitherapy only
Number of subjects: 56
Study 21724197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide
Number of subjects: 218
Study 21724197 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (high dose)
Number of subjects: 218
Study 21724197 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid (low dose)
Number of subjects: 218
Study 19886372 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO before MIV
Number of subjects: 33
Study 19886372 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO after MIV
Number of subjects: 33
Study 19886372 — intervention group
Group type: COMPARATOR
Intervention: No ISO (Control)
Number of subjects: 33
Study 17907493 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored with resin composites (Group 2a)
Number of subjects: 90
Study 17907493 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored with translucent glass fiber posts and resin composites (Group 2b)
Number of subjects: 90
Study 17907493 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored with resin composites (Group 3a)
Number of subjects: 90
Study 17907493 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored with translucent glass fiber posts and resin composites (Group 3b)
Number of subjects: 90
Study 17907493 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored with resin composites (Group 4a)
Number of subjects: 90
Study 17907493 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored with translucent glass fiber posts and resin composites (Group 4b)
Number of subjects: 90
Study 17907493 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored with resin composites (Group 5a)
Number of subjects: 90
Study 17907493 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored with translucent glass fiber posts and resin composites (Group 5b)
Number of subjects: 90
Study 17907493 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 90
Study 15180757 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab (>/= 0.016 mg/kg/IgE [IU/ml] per 4 weeks)
Number of subjects: 405
Study 15180757 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 405
Study 12092301 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 4
Study 12092301 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur-uracil-folonic acid
Number of subjects: 4
Study 12092301 — intervention group
Group type: COMPARATOR
Intervention: 5-FU with folonic acid
Number of subjects: 4
Study 9650008 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 48
Study 9650008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7640969 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Standing Test (FST) administered by two testers
Number of subjects: 13
Study 7640969 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Standing Test (FST) administered to adolescents with SCI
Number of subjects: 13
Study 7640969 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Standing Test (FST) administered to able-bodied young adults
Number of subjects: 13
Study 29747087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight-loss intervention (very-low-calorie diet for 6 weeks)
Number of subjects: 52
Study 29747087 — intervention group
Group type: COMPARATOR
Intervention: No-weight loss control group
Number of subjects: 52
Study 27034058 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-hydrolysed lactose-free milk
Number of subjects: 97
Study 27034058 — intervention group
Group type: COMPARATOR
Intervention: Commercially available lactose-free milk
Number of subjects: 97
Study 26672080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 2202
Study 26672080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2202
Study 26672080 — intervention group
Group type: EXPERIMENTAL
Intervention: NCS patients
Number of subjects: 2202
Study 23946328 — intervention group
Group type: EXPERIMENTAL
Intervention: CPOP-R (pixantrone-based regimen)
Number of subjects: 0
Study 23946328 — intervention group
Group type: COMPARATOR
Intervention: CHOP-R (doxorubicin-based therapy)
Number of subjects: 0
Study 21058885 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodanza intervention (n=27)
Number of subjects: 59
Study 19635613 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene (20 or 40 mg) combined with conjugated estrogens (0.625 or 0.45 mg)
Number of subjects: 3397
Study 19635613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3397
Study 16911780 — intervention group
Group type: EXPERIMENTAL
Intervention: Email communication initiated by the clinic
Number of subjects: 173
Study 16911780 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education provided via email
Number of subjects: 173
Study 15181095 — intervention group
Group type: COMPARATOR
Intervention: Dihydrotestosterone (DHT) - daily transdermal, n = 17, for 3 months
Number of subjects: 75
Study 15181095 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human chorionic gonadotropin (rhCG) - subcutaneous, two injections weekly, n = 20, for 3 months
Number of subjects: 75
Study 10886297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases (paternal history of CHD)
Number of subjects: 822
Study 9290542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotoxic group
Number of subjects: 0
Study 9290542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic group
Number of subjects: 0
Study 9290542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed group
Number of subjects: 0
Study 9290542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic ATN with advancing age
Number of subjects: 0
Study 8302148 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous labetalol (1.0‐1.5 mg/Kg, repeated bolus of 10 mg/bolus)
Number of subjects: 14
Study 8302148 — intervention group
Group type: COMPARATOR
Intervention: No labetalol (Control group A)
Number of subjects: 14
Study 3519693 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-inspection group
Number of subjects: 31
Study 3519693 — intervention group
Group type: COMPARATOR
Intervention: Traditional group
Number of subjects: 31
Study 3519693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 27879536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health promotion program
Number of subjects: 70
Study 27879536 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 70
Study 26314349 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic ring (WR)
Number of subjects: 400
Study 26314349 — intervention group
Group type: COMPARATOR
Intervention: No silastic ring (NR)
Number of subjects: 400
Study 24237300 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha lozenge 500 IU/day
Number of subjects: 169
Study 24237300 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha lozenge 1500 IU/day
Number of subjects: 169
Study 24237300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 22398262 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding low level laser therapy (LLLT) to ultrasound (US) and exercise
Number of subjects: 42
Study 22398262 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US) and exercise
Number of subjects: 42
Study 20579370 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in using the new measure and undertaking observations of designated residents (intervention condition)
Number of subjects: 80
Study 20579370 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 80
Study 20579370 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in using the new measure (intervention condition)
Number of subjects: 80
Study 18306449 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz EAS
Number of subjects: 62
Study 18306449 — intervention group
Group type: COMPARATOR
Intervention: 120 Hz EAS
Number of subjects: 62
Study 16011981 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (1.5 g daily for 8 weeks)
Number of subjects: 20
Study 16011981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 8 weeks)
Number of subjects: 20
Study 12422137 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal
Number of subjects: 20
Study 12422137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 20
Study 10361382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (180 mg orally)
Number of subjects: 28
Study 10361382 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg in an i.v. bolus injection)
Number of subjects: 28
Study 10361382 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone plus Pyridostigmine
Number of subjects: 28
Study 10361382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10361382 — intervention group
Group type: COMPARATOR
Intervention: TRH plus Placebo
Number of subjects: 28
Study 10361382 — intervention group
Group type: COMPARATOR
Intervention: TRH plus Naloxone
Number of subjects: 28
Study 10361382 — intervention group
Group type: COMPARATOR
Intervention: TRH plus Pyridostigmine
Number of subjects: 28
Study 10361382 — intervention group
Group type: COMPARATOR
Intervention: TRH plus Naloxone plus Pyridostigmine
Number of subjects: 28
Study 7732443 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble, hyperosmolar, radiocontrast material via nasogastric tube on the third postoperative day
Number of subjects: 115
Study 7732443 — intervention group
Group type: COMPARATOR
Intervention: Control group managed without radiocontrast material, received a suppository on the third day
Number of subjects: 115
Study 2028630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 80 mg tid
Number of subjects: 1
Study 2028630 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study 7037504 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (betamethasone valerate or clobetasone butyrate)
Number of subjects: 10
Study 30302838 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes guidelines usage
Number of subjects: 336
Study 30302838 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of stroke as a diabetes-related complication
Number of subjects: 336
Study 30302838 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of diabetes pathology
Number of subjects: 336
Study 30302838 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge to advise on laboratory results
Number of subjects: 336
Study 30302838 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge to improve outcomes through lifestyle changes
Number of subjects: 336
Study 30302838 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of stroke as a complication of type 2 diabetes
Number of subjects: 336
Study 30302838 — intervention group
Group type: COMPARATOR
Intervention: Knowledge to advise on medications
Number of subjects: 336
Study 30302838 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of modifiable risk factors (hypertension, smoking, dyslipidaemia)
Number of subjects: 336
Study 28005446 — intervention group
Group type: EXPERIMENTAL
Intervention: Agave tequilana Weber inulin (24g) with 500mL lemon water and 75g glucose
Number of subjects: 14
Study 28005446 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink with 500mL lemon drink and 75g glucose
Number of subjects: 14
Study 25620217 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look laparoscopy (SLL)
Number of subjects: 216
Study 25620217 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 216
Study 25150117 — intervention group
Group type: EXPERIMENTAL
Intervention: MB-6
Number of subjects: 72
Study 25150117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 21479888 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (n = 80) - received training and conducted 12 weeks of outreach
Number of subjects: 158
Study 21479888 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 78)
Number of subjects: 158
Study 19848199 — intervention group
Group type: EXPERIMENTAL
Intervention: Buxu Huayu Qutan Decoction (BHQD)
Number of subjects: 40
Study 19848199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 18001620 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid therapy
Number of subjects: 0
Study 15680021 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 85
Study 15680021 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 85
Study 15680021 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 85
Study 11350538 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg
Number of subjects: 10
Study 11350538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9424404 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite allergen (HDM) extract inhalation challenge in atopic asthmatics (AA)
Number of subjects: 31
Study 9424404 — intervention group
Group type: COMPARATOR
Intervention: House dust mite allergen (HDM) extract inhalation challenge in atopic non-asthmatics (AN)
Number of subjects: 31
Study 9424404 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL fluid from AA
Number of subjects: 31
Study 7708638 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin test
Number of subjects: 0
Study 7708638 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood chemiluminescence (CL) tests with M. tuberculosis (BCG and staphylococcus strains)
Number of subjects: 0
Study 7708638 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood chemiluminescence (CL) tests with staphylococcus
Number of subjects: 0
Study 2972170 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen/gestagen replacement therapy
Number of subjects: 110
Study 2972170 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of estrogen/gestagen replacement therapy
Number of subjects: 110
Study 2972170 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (implied control)
Number of subjects: 110
Study 30395011 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose of quadrivalent, split‐virion, inactivated influenza vaccine (IIV4)
Number of subjects: 1950
Study 30395011 — intervention group
Group type: COMPARATOR
Intervention: Half dose of quadrivalent, split‐virion, inactivated influenza vaccine (IIV4)
Number of subjects: 1950
Study 30395011 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose of IIV4
Number of subjects: 1950
Study 30395011 — intervention group
Group type: COMPARATOR
Intervention: Half dose of IIV4
Number of subjects: 1950
Study 27348853 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil patient-controlled analgesia (RPCA)
Number of subjects: 408
Study 27348853 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (EA)
Number of subjects: 408
Study 27348853 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil patient-controlled analgesia (RPCA) among those who received analgesia
Number of subjects: 408
Study 27348853 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (EA) among those who received analgesia
Number of subjects: 408
Study 26666295 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) using Routine Outcome Monitoring (ROM) in intervention teams
Number of subjects: 364
Study 26666295 — intervention group
Group type: COMPARATOR
Intervention: Usual decision making without specific SDM or ROM instructions in control teams
Number of subjects: 364
Study 26666295 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) using Routine Outcome Monitoring (ROM)
Number of subjects: 364
Study 23718142 — intervention group
Group type: EXPERIMENTAL
Intervention: SHK (heart-kidney)
Number of subjects: 1801
Study 23718142 — intervention group
Group type: EXPERIMENTAL
Intervention: SHLi (heart-liver)
Number of subjects: 1801
Study 23718142 — intervention group
Group type: EXPERIMENTAL
Intervention: SLuLi (lung-liver)
Number of subjects: 1801
Study 23718142 — intervention group
Group type: EXPERIMENTAL
Intervention: SLuK (lung-kidney)
Number of subjects: 1801
Study 21056689 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 μg/wk peginterferon alfa‐2a for 48 weeks
Number of subjects: 85
Study 21056689 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 μg/wk peginterferon alfa‐2a for 48 weeks
Number of subjects: 85
Study 21056689 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 μg/wk peginterferon alfa‐2a for 48 weeks (among those with undetectable HCV RNA at week 12)
Number of subjects: 85
Study 21056689 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 μg/wk peginterferon alfa‐2a for 48 weeks (among those with undetectable HCV RNA at week 12)
Number of subjects: 85
Study 19769705 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort) Maintenance And Reliever Therapy (Symbicort SMART)
Number of subjects: 908
Study 16996784 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of risk factors in oral cancer; 100% identified tobacco as a risk factor.
Number of subjects: 240
Study 16996784 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of risk factors in oral cancer; 90% identified alcohol as a risk factor.
Number of subjects: 240
Study 16996784 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of risk factors in oral cancer; 50.7% identified sun exposure with labial cancer.
Number of subjects: 240
Study 16996784 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice on prevention of oral cancer; 51.4% routinely gave advice to patients.
Number of subjects: 240
Study 16996784 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment of training; 57.1% did not consider themselves sufficiently trained to discover suspected oral cancer lesions.
Number of subjects: 240
Study 16996784 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of academic training; 84.3% recognized insufficient academic training on early diagnosis and prevention of oral cancer.
Number of subjects: 240
Study 16871743 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (3 times per week, 4 hours per session, using Fresenius dialysers with polysulfone membranes and bicarbonate buffer with glucose)
Number of subjects: 42
Study 16871743 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 42
Study 16871743 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 healthy volunteers)
Number of subjects: 42
Study 12518005 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation to screening
Number of subjects: 77080
Study 9516091 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized tobramycin 80 mg b.i.d. for 12 months
Number of subjects: 22
Study 9516091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7747578 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional application of 1% cyclopentolate hydrochloride (30 microliters drops)
Number of subjects: 8
Study 7747578 — intervention group
Group type: COMPARATOR
Intervention: Inner canthus application of 1% cyclopentolate hydrochloride (30 microliters drops)
Number of subjects: 8
Study 2701817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative portal chemotherapy without blood transfusion
Number of subjects: 469
Study 2701817 — intervention group
Group type: COMPARATOR
Intervention: Blood transfusions during curative resection
Number of subjects: 469
Study 215985 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 38
Study 215985 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin
Number of subjects: 38
Study 215985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30760138 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive osteoarthritis group
Number of subjects: 56
Study 30760138 — intervention group
Group type: COMPARATOR
Intervention: Non-progressive osteoarthritis group
Number of subjects: 56
Study 30760138 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative wrist osteoarthritis progression
Number of subjects: 56
Study 30760138 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative morphological changes
Number of subjects: 56
Study 30760138 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioscaphoid angle change
Number of subjects: 56
Study 28719280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) - one round
Number of subjects: 3612
Study 28719280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) - two rounds
Number of subjects: 3612
Study 26011507 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Number of subjects: 15